These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38901970)

  • 1. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis.
    Zhu Y; Liu K; Zhu H
    Int J Gynecol Cancer; 2024 Oct; 34(10):1570-1579. PubMed ID: 38901970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.
    Zhu Y; Liu K; Zhu H
    J Gynecol Oncol; 2024 Jun; ():. PubMed ID: 38857909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.
    Huo G; Song Y; Chen P
    J Gynecol Oncol; 2024 Sep; 35(5):e83. PubMed ID: 38606824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
    Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
    J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
    Lubinga SJ; Walder L; Burton M; Shen Q
    J Med Econ; 2024; 27(1):1212-1221. PubMed ID: 39254489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
    Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
    Kim J; Lim J; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim DY
    Gynecol Oncol; 2023 Dec; 179():106-114. PubMed ID: 37976756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
    N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
    Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
    J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
    Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer.
    Huo G; Song Y; Liu W; Guo H; Chen P
    Front Pharmacol; 2024; 15():1391896. PubMed ID: 38966552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis.
    Huang D; Li S; Bai Y; Wang Y
    BMC Cancer; 2024 Oct; 24(1):1298. PubMed ID: 39433998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
    Fleeman N; Houten R; Nevitt S; Mahon J; Beale S; Boland A; Greenhalgh J; Edwards K; Maden M; Bhattacharyya D; Chaplin M; McEntee J; Chow S; Waddell T
    Health Technol Assess; 2024 Aug; 28(49):1-190. PubMed ID: 39252678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.